CLINICAL_TRIALS
trial_result
· 2023-10-03
Clinical Trial Update: BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours [Phase 1]
Summary
Phase 1 trial of BI 6727 given IV every 3 weeks in patients with solid tumours has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2023-10-03